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Genetic inhibition of PI3K signaling increases energy
expenditure, protects from obesity and metabolic
syndrome, and extends longevity. Here, we show
that two pharmacological inhibitors of PI3K, CNIO-
PI3Ki and GDC-0941, decrease the adiposity of
obese mice without affecting their lean mass. Long-
term treatment of obese mice with low doses of
CNIO-PI3Ki reduces body weight until reaching a
balance that is stable for months as long as the treat-
ment continues. CNIO-PI3Ki treatment also amelio-
rates liver steatosis and decreases glucose serum
levels. The above observations have been recapitu-
lated in independent laboratories and using different
oral formulations of CNIO-PI3Ki. Finally, daily oral
treatment of obese rhesus monkeys for 3 months
with low doses of CNIO-PI3Ki decreased their
adiposity and lowered their serum glucose levels,
in the absence of detectable toxicities. Therefore,
pharmacological inhibition of PI3K is an effective
and safe anti-obesity intervention that could reverse
the negative effects of metabolic syndrome in
humans.
INTRODUCTION
The phosphatidylinositol 3-kinase type I (PI3K) family is at the
center of the most conserved aging-inducing pathway in evolu-
tion. Indeed, partial genetic attenuation of the PI3K signaling
cascade at multiple levels results in lifespan extension in worms,
flies, andmice (Barzilai et al., 2012; Fontana et al., 2010; Kenyon,
2010). In mammals, the PI3K family comprises four related lipid
kinases (PI3Ka, b, g, d) that respond to multiple receptors by
generating the second messenger phoshpatidylinositol-3,4,5-
trisphosphate (PIP3), which in turn has a wide range of cellular558 Cell Metabolism 21, 558–570, April 7, 2015 ª2015 Elsevier Inc.effects (Vanhaesebroeck et al., 2010). In support of the role of
PI3K in promoting aging, genetically engineered mice with
decreased PI3Ka activity or with decreased overall PI3K
signaling (due to overexpression of the PIP3 phosphatase
PTEN) are long lived (Foukas et al., 2013; Ortega-Molina et al.,
2012). Furthermore, dietary restriction (DR) extends lifespan in
most tested animal models, and this is partly mediated in worms
and flies by reduced PI3K pathway activity (Fontana et al., 2010).
In rhesus monkeys, DR extends healthspan (Mattison et al.,
2012), and it may also extend longevity (Colman et al., 2009).
Finally, in humans, there is evidence that DR improves health
(Cava and Fontana, 2013), and it also downregulates the PI3K
pathway (Mercken et al., 2013).
At the opposite end of the beneficial effects of reduced PI3K
andDR are the detrimental effects of hypercaloric and fat-rich di-
ets. Hypercaloric diets initially result in obesity due to the storage
of the extra energy in the adipose tissue. However, the contin-
uous caloric overload eventually results in the aberrant accumu-
lation of lipids in non-adipose tissues (Virtue and Vidal-Puig,
2010). The direct pathological consequence of chronic hyper-
caloric diets is a multi-systemic deterioration known as meta-
bolic syndrome, which is characterized by insulin resistance,
liver steatosis, atherogenic cardiovascular disease, dyslipide-
mia, and systemic inflammation (Kaur, 2014). Of note, the co-
morbidities associated with metabolic syndrome overlap with
some of the most important aging-associated diseases, namely
diabetes, cardiovascular and cerebrovascular diseases, and
cancer (Gurevich-Panigrahi et al., 2009; Pi-Sunyer, 2009).
A substantial amount of evidence indicates that PI3K plays
an important role in setting the balance between nutrient
storage and nutrient consumption. In particular, mice with sys-
temic overall reduction of PI3K signaling (due to PTEN overex-
pression) have increased energy expenditure and are protected
from obesity and from metabolic syndrome (Garcia-Cao et al.,
2012; Ortega-Molina et al., 2012). The inhibition of single PI3K
isoforms may also achieve similar metabolic effects, as is the
case of mice with partial decrease of PI3Ka activity (Foukas
et al., 2013), complete loss of PI3Kg activity (Becattini et al.,
2011; Kobayashi et al., 2011), combined complete loss of
PI3Kg and PI3Kb activities (Perino et al., 2014), and liver-specific
complete loss of PI3Ka (Chattopadhyay et al., 2011). Finally,
the role of PI3K in human obesity has received direct experi-
mental support from the observation of a strong association
between hyperactive PI3K signaling due to germline PTEN hap-
loinsufficiency and obesity (Pal et al., 2012).
In summary, separate lines of research on longevity, dietary
restriction, obesity, and metabolic syndrome have converged
on the concept that moderate downregulation of PI3K signaling
activity has the potential to improve health and provide protec-
tion from obesity and from its associated diseases. Following
on this, it is of great importance to determine the potential ben-
efits of pharmacological treatments that reduce PI3K activity.
Here, we show that PI3K inhibitors, at low doses, can safely
reduce obesity and ameliorate metabolic syndrome in obese
mice and monkeys.
RESULTS
Effects of CNIO-PI3Ki on Glucose Homeostasis
In this work, we use two small compounds with high inhibitory
potency and selectivity against PI3K. GDC-0491 (also known
as pictilisib) is a well-characterized inhibitor of PI3Ka (IC50
3 nM), PI3Kd (IC50 3 nM), PI3Kb (IC50 33 nM), and PI3Kg (IC50
75 nM), with no relevant inhibitory activity against other kinases,
minimal access to the brain, and a good pharmacokinetic pro-
file (Salphati et al., 2012; Workman et al., 2010). We also use
CNIO-PI3Ki, an inhibitor developed at the Spanish National
Cancer Research Center (CNIO) and already used in previous
reports (Mun˜oz-Espı´n et al., 2013; Ortega-Molina et al., 2012).
CNIO-PI3Ki inhibits PI3Ka (IC50 2.4 nM), PI3Kd (IC50 2.5 nM),
and PI3Kg (IC50 44 nM) (Figure S1A), it shows no relevant
inhibitory activity against 284 tested kinases including mTOR
(Figure S1A; Table S1), has minimal access to the brain (Fig-
ure S1B), and has a good pharmacokinetic profile in mice
(Figure S1C). Of note, the half-life of the elimination phase
of CNIO-PI3Ki by oral administration is 4 hr in mice, thus allow-
ing for a substantial period of activity upon administration
(Figure S1C).
The beneficial metabolic effects of overall PI3K signaling
reduction, or isoform-specific genetic inhibition of PI3Kg and
PI3Kb, have been attributed to an increase in energy expendi-
ture, and thereby to an attenuation of nutrient storage in favor
of nutrient consumption (Becattini et al., 2011; Garcia-Cao
et al., 2012; Ortega-Molina et al., 2012; Perino et al., 2014).
Several tissues and mechanisms can conceivably contribute to
the increased energy expenditure associated with PI3K inhibi-
tion. We have previously shown that GDC-0941 and CNIO-
PI3Ki increase thermogenesis (i.e., energy expenditure) in
cultured brown adipocytes (Ortega-Molina et al., 2012). Given
the fact that GDC-0941 and CNIO-PI3Ki inhibit several PI3K
isoforms, we used shRNA inhibition to identify the isoform
responsible for the regulation of thermogenic activity in brown
adipocytes. Only shRNA inhibition of PI3Ka, but not of other
PI3Ks, resulted in upregulation of Ucp1 and Pgc1a mRNAs in
forskolin-stimulated brown adipocytes (Figure S1D). This finding
reinforces the concept that PI3Ka inhibition is a relevant medi-
ator of the link between PI3K and metabolism, which is in agree-
ment with previous observations in mice with partial decrease ofCPI3Ka activity (Foukas et al., 2013). This does not preclude that
inhibition of other PI3K isoforms, particularly PI3Kg and possibly
also PI3Kb, could contribute to increased energy expenditure
through mechanisms other than brown adipocyte thermogene-
sis (Becattini et al., 2011; Perino et al., 2014).
As a first step to use CNIO-PI3Ki in mice, we began by
measuring its serum levels by mass spectrometry. After a single
oral dose of 15 mg/kg, the drug reached a serum concentration
of 2–3 mg/ml (4–6 mM) during 1–6 hr post-administration, and it
was completely cleared after 24 hr (Figure 1A). Given the direct
role of PI3K in insulin signaling, we examined the effect of
CNIO-PI3Ki on glucose levels in fasted C57BL6 mice. A peak
of glucose of about 150 mg/dl was observed between 30 min
and 2 hr post-administration of the drug (Figure 1B). These levels
of glycemia are comparable to the normal levels of glucose in ad
libitum-fed mice (Goren et al., 2004) (see also Figure 1B, right
panel). As expected, both GDC-0941 (75 mg/kg) and CNIO-
PI3Ki (15 mg/kg) produced a notable reduction in the levels of
phosphorylated AKT (P-Ser473-AKT) in liver and interscapular
brown adipose tissue (iBAT) at 1 hr post-administration (Fig-
ure 1C). Inhibition of P-AKT was less prominent, although still
detectable, at 6 hr post-administration (Figure 1C). Reductions
in phosphorylated FOXO1, FOXO3, and 4EBP1 were also
notable at 1 hr post-administration particularly in iBAT (Fig-
ure S1E). Similarly, PI3K inhibition resulted in a remarkable upre-
gulation of the hepatic gluconeogenic transcriptional program
(measured by G6pc mRNA) at 1 hr post-treatment, but G6pc
levels returned close to basal conditions after 6 hr (Figure 1D).
Therefore, at the doses used, PI3K inhibitors produce a transient
glycemic response within physiological range.
In agreement with our previous data (Ortega-Molina et al.,
2012), the levels of protein UCP1 increased in the BAT at 6 hr
post-administration of CNIO-PI3Ki (15 mg/kg) (Figure S1F). As
expected from the kinetics of CNIO-PI3Ki clearance, the levels
of P-AKT and P-FOXO1 were normalized in the iBAT after
24 hr, but the levels of UCP1 were still elevated (Figure S1F).
This is consistent with the long half-life of protein UCP1 (Puig-
server et al., 1992). Extending our previous findings on the ability
of CNIO-PI3Ki to activate the brown adipocytes interspersed
within white adipose depots (Ortega-Molina et al., 2012), we
also observed an increase in the expression of Ucp1 in subcu-
taneous white adipose tissue (WAT) (inguinal or iWAT) and in
visceral WAT (epididymal or eWAT, and perirenal or rWAT) at
6 hr post-administration, but this effect disappeared after
24 hr (Figure 1E).
PI3Ki Reduces Obesity
To test whether pharmacological inhibition of PI3K could revert
obesity we began by using a short-term assay with daily admin-
istration of a relatively high dose of inhibitors. Male mice of
10months of age that had been fed with high-fat diet (HFD) since
2 months of age were used for these assays. High-fat-fed mice
had a body weight that was 44% above the weight of mice fed
with standard diet (SD) (Figure S2A), and this increase in body
weight was exclusively due to an increase in adiposity (and not
in lean mass) (Figure S2B). As expected after 8 months in HFD,
these mice had developed insulin resistance (Figure S2C). Addi-
tional parameters, such as serum leptin, free fatty acids, and tri-
glycerides (Figures S2D–S2F) were consistent with the HFDell Metabolism 21, 558–570, April 7, 2015 ª2015 Elsevier Inc. 559
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Figure 1. Effects of PI3K Inhibition In Vivo
(A) Detection of CNIO-PI3Ki in serum. CNIO-PI3Ki 15 mg/kg was orally administered by gavage (C57BL6 males n = 4 per group; 3–4 months old). Detection was
made by mass spectrometry at the indicated times. Dots correspond to individual values and red lines to the average.
(B) Left panel, glucose serum levels at the indicated times after CNIO-PI3Ki 15 mg/kg orally administered by gavage (C57BL6males n = 8–9 per group; 4 months
old). Mice were fasted overnight, treated by gavage, and maintained under fasting. Values correspond to the average ± s.d. Right panel, glucose serum levels of
ad libitum-fed mice (C57BL6 males n = 16; 3 months old). Dots correspond to individual values and the red line to the average.
(C) Immunoblot analyses of the indicated proteins in liver and iBAT extracts 1 or 6 hr after oral administration by gavage of vehicle, GDC-0941 75mg/kg, or CNIO-
PI3Ki 15 mg/kg.
(D) G6pc mRNA expression relative to b-actin in liver of mice treated by gavage with vehicle or CNIO-PI3Ki 15 mg/kg at the indicated times.
(E) Ucp1 mRNA levels in inguinal (iWAT), epididymal (eWAT), and perirenal (rWAT) white adipose tissue of mice treated by gavage with vehicle or CNIO-PI3Ki
15 mg/kg at the indicated times. Values are relative to the levels in vehicle-treated mice. Bars correspond to the average ± s.d.
Mice were under ad libitum feeding all the time in the assays shown in (A), (C), (D), and (E). Statistical significance was determined by the two-tailed Student’s
t test: *p < 0.05, ***p < 0.001. See also Figure S1 and Table S1.regime and the obese status of these mice. Food and water
intake were also measured (Figure S2G).
Diet-induced obese mice were dosed daily by gavage with
10 or 15 mg/kg of CNIO-PI3Ki or with 10 or 75 mg/kg of
GDC-0941 for a period of 10 days (see Figure 2A). During the
assay, mice remained fed ad libitum with HFD, and food
intake did not change during the treatment period (Figure 2B).560 Cell Metabolism 21, 558–570, April 7, 2015 ª2015 Elsevier Inc.Interestingly, despite maintaining their normal high-fat food
intake, body weight decreased significantly upon treatment
with the PI3K inhibitors (Figure 2C). In the most effective case
(CNIO-PI3Ki at 15 mg/kg), mice reached the same body weight
as non-obese mice fed with SD in a period of 10 days.
Treatment with CNIO-PI3Ki at 10 mg/kg or with GDC-0941
at 75 mg/kg decreased body weight less abruptly, but
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Figure 2. Body Weight Reduction and Decreased Adiposity after CNIO-PI3Ki Treatment
(A) Schematic diagram showing the administration of PI3K inhibitors or vehicle by gavage at the indicated days (gray boxes) to diet-induced obesemice (C57BL6/
CBA males n = 4–7 per group; 10 months old).
(B) Average food intake per day during treatment with PI3K inhibitors (days marked in gray in A). Color code as in (A).
(C) Body weight change relative to day 0 during the treatment (left) or at the last day of treatment (right). For reference, the panel to the right includes a dotted red
line corresponding to the relative body weight of control male mice fed with SD. Color code as in (A).
(D) Ad libitum glucose serum levels at the end of treatment (day 13). Color code as in (A).
(E) Adiposity (top) and lean mass (bottom) at the indicated times according to the diagram in (A) measured by dual-energy X-ray absorptiometry (DXA). Adiposity
values correspond to the percentage of fat relative to the sum of lean and fat masses. For reference, the graphs include dotted red lines corresponding to
adiposity and lean mass of control male mice fed with SD. Right panel, representative DXA images of two individual mice treated with vehicle or CNIO-PI3Ki
(15 mg/kg), respectively.
All values correspond to average ± s.d., and statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001. See also
Figure S2.
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significantly (Figure 2C). In agreement with the transient effect
of CNIO-PI3Ki on glycemia (see above Figure 1B), the ad libi-
tum glucose levels in the treated mice were normal 3 days after
the end of the treatment (Figure 2D). To distinguish whether
PI3K inhibitors result in loss of fat mass or loss of lean mass,
we employed dual-energy X-ray absorptiometry (DXA) before,
during, and after treatment (Figure 2E, right panel). Importantly,
obese mice treated with CNIO-PI3Ki 15 mg/kg showed a pro-
gressive reduction in adiposity that at the end of the treatment
was comparable to the adiposity of non-obese mice (Figure 2E,
left upper panel). A tendency to decrease adiposity was
observed with CNIO-PI3Ki 10 mg/kg and with GDC-0941
75 mg/kg (Figure 2E, left upper panel). In all cases, lean mass
remained stable (Figure 2E, left lower panel), thereby indicating
that the weight loss produced by PI3K inhibition is selectively
due to the loss of fat mass. Collectively, these data indicate
that pharmacological inhibition of PI3K induces a significant
decrease in adiposity and body weight in diet-induced obese
mice.
PI3Ki Decreases Visceral Fat and Hepatic Steatosis
Examination of tissues from the above-described mice (at day
13) revealed that mice treated with CNIO-PI3Ki 15 mg/kg
presented a normal coloration of the liver, which was in contrast
to the pale color characteristic of obese mice (Figure 3A). More
dramatically, vehicle-treated obese mice presented large
masses of adipose tissue in the thoracic cavity around the heart
(pericardial fat), and this abnormal accumulation of fat was
essentially absent in mice treated for 10 days with CNIO-PI3Ki
15 mg/kg (Figure 3A). Mice treated with CNIO-PI3Ki 10 mg/kg
and GDC-0941 75 mg/kg presented a partial improvement
compared with vehicle-treated mice (Figure 3A). Histological
analysis of the liver indicated a clear reduction in lipid accumula-
tion in mice treated with CNIO-PI3Ki, 10 mg/kg or 15 mg/kg, or
with 75 mg/kg GDC-0941 (Figure 3B). Examination of eWAT,
perirenal, and pericardial adipose tissue revealed focal areas
of brown-like adipocytes (Figure 3B), which reflects a process
known as browning (Wu et al., 2013). Browning was particularly
prominent in mice treated with CNIO-PI3Ki 15 mg/kg, intermedi-
ate in the case of CNIO-PI3Ki 10 mg/kg and GDC-0941
75 mg/kg, and absent in the case of GDC-0941 10 mg/kg (Fig-
ure 3B). Reduced lipid content was also observed in the iBAT
following the same trends among treatments as in the other tis-
sues (Figure 3B).
The arcuate nucleus of the hypothalamus (ARC) is a master
regulator of metabolism (Sohn et al., 2013; Yeo and Heisler,
2012) exposed to peripheral circulation through the median
eminence, a circumventricular organ that lacks brain-blood bar-
rier (Cone et al., 2001). We wondered whether administration of
CNIO-PI3Ki (15 mg/kg) or GDC-0941 (75 mg/kg) could affect the
expression of the main orexigenic (NPY and AgRP) and anorex-
igenic (CART and POMC) neuropeptides in the arcuate nucleus.
However, we did not detect any significant alteration at 1 hr or
6 hr post oral administration (Figure S3). These results indicate
a lack of a hypothalamic effect, at least at the level of the ARC,
which is the hypothalamic nucleus most exposed to circulating
factors.
We conclude that short-term treatment with PI3K inhibitors re-
duces abnormal lipid accumulation, induces browning within562 Cell Metabolism 21, 558–570, April 7, 2015 ª2015 Elsevier Inc.white adipose depots, and activates the iBAT, without affecting
the ARC.
Loss of Adiposity by Long-Term Treatment
with Low-Dose CNIO-PI3Ki
A desirable feature for an anti-obesity treatment is to retain activ-
ity at low doses administered during prolonged periods of time.
This not only increases the safety margins, but will presumably
produce a gradual loss of body weight more amenable to med-
ical supervision. With this in mind, we formulated CNIO-PI3Ki
for administration in the drinking water or mixed with the food
(see Experimental Procedures). By mass spectrometry, we
confirmed stability (> 90%) of the compound when dissolved in
water (for at least 1 week at room temperature) and also when
mixed with the food (for at least 4 months at 4C).
Male mice fed with HFD (starting at 2 months of age) or with
SD, all of 10 months of age, were used for these assays (see Fig-
ure S2). HFD-fed and SD-fedmice were randomly separated into
two groups that were treated with CNIO-PI3Ki or its vehicle. For
administration through the drinking water we chose a CNIO-
PI3Ki concentration of 0.1 mg/ml, which corresponds approxi-
mately to an accumulated daily dose of 10 mg/kg. Mice had
continuous and ad libitum access to water (with vehicle or
drug) and to food (HFD or SD). This administration regime re-
sulted in detectable, albeit highly variable, serum levels of
CNIO-PI3Ki (63 ± 54 ng/ml, average ± standard deviation
[s.d.], n = 12 pooled SD andHFDmice after 2.5months of contin-
uous treatment; Figure S4A). Variability was expected given the
fact that drinking was ad libitum and thereby heterogeneous
from mouse to mouse. No evidence of drug accumulation was
obtained in the inguinalWAT, iBAT, or in the liver after 2.5months
of treatment (Figure S4A). The administration regime used in this
long-term assay is notoriously different from the short-term
assay shown before; nonetheless, it is worth mentioning that
the average serum concentration of drug achieved by ad libitum
drinking (CNIO-PI3Ki 0.1 mg/ml) is around 40-fold lower than
the peak of drug achieved 1–6 hr post-gavage (CNIO-PI3Ki
15 mg/kg).
A progressive decrease in body weight was noticeable in
obese mice soon after exposing them to CNIO-PI3Ki (Figure 4A).
Body weight loss lasted for 50 days, and then it stabilized at a
level that was 20% lower than the body weight of vehicle-treated
mice. Importantly, food intake remained unaltered during the
entire observation period (Figure 4B). This behavior is compat-
ible with the idea that CNIO-PI3Ki increases energy expenditure,
thus lowering the body weight at whichmice are in energetic bal-
ance. Of note, mice fed with SD did not show any alteration in
their body weight in the presence of CNIO-PI3Ki (Figure 4A).
The fact that CNIO-PI3Ki is only active on HFD-fed mice, but
not on SD-fed mice, is an attractive safety feature, and it sug-
gests that CNIO-PI3Ki may act selectively on energy expenditure
induced by nutritional overload. Longitudinal analyses of body
composition by DXA indicated that weight loss of obese mice
treated with CNIO-PI3Ki was exclusively due to a loss of
adiposity, with no alterations in lean mass (Figure 4C), and this
was confirmed by the weight of epididymal and inguinal adipose
depots, as well as by the macroscopic observation of pericardial
and perirenal fat (Figure S4B). Further supporting the decreased
adiposity, leptin serum levels were also significantly reduced in
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Figure 3. Reduced Liver Steatosis and Increased Browning after CNIO-PI3Ki Treatment
(A) Representative pictures of liver and fat around lung and heart (pericardial fat) in vehicle- and PI3Ki-treated mice at day 13. Bars correspond to 0.5 cm.
(B) Representative pictures of H&E-stained sections of the indicated tissues at day 13. eWAT is epididymalWAT, and iBAT is interscapular BAT. In the perirenal fat,
K indicates the kidney; in the pericardial fat, L indicates the lungs and H indicates the heart. Bars in the low-magnification pictures correspond to 500 mm,with the
exception of pericardial fat pictures,wherebars correspond to2mm;all bars in thehigh-magnification insets correspond to50mm.Miceare the sameas inFigure2.
See also Figure S3.obese mice at the end of the long-term treatment with CNIO-
PI3Ki (Figure 4D). Also, we observed a tendency toward
decreased levels of serum triglycerides (Figure 4E), and no alter-
ation in cholesterol levels (Figure 4F). In summary, long-term
pharmacological treatment of obese mice with a low dose of
CNIO-PI3Ki produces a progressive loss of adiposity that stabi-
lizes at a lower body weight.CCorrection of Metabolic Syndrome by Long-Term
Low-Dose CNIO-PI3Ki
Examination of the liver of the mice from the above assay (see
Figure 4A) revealed a complete histological correction of stea-
tosis in long-term CNIO-PI3Ki-treated HFD-fed mice (Figure 5A)
and a tendency to have a lower liver weight (Figure S4B). This
was accompanied by a significant decrease in serum alanineell Metabolism 21, 558–570, April 7, 2015 ª2015 Elsevier Inc. 563
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Figure 4. Reduction of Obesity by Long-Term CNIO-PI3Ki Treatment
(A) Left, body weight curves during 2.5 months of treatment with vehicle or CNIO-PI3Ki (0.1 mg/ml) in the drinking water. All mice were 11 months old at the
beginning of the treatments. HFD, mice fed with high-fat diet since 2 months of age; SD, mice fed standard diet (C57BL6 males n = 5–7 per group). Right, body
weights at the end of the treatment relative to the weight of SD-fed and vehicle-treated mice.
(B) Absolute (left) and relative (right) food and water intake during treatment of HFD-fed mice. Intake was measured in periods of 3 days, and in a total of four
periods distributed during the entire treatment period.
(C) Adiposity (left) and lean mass (right) measured by dual-energy X-ray absorptiometry (DXA) at the indicated times. Adiposity values correspond to the per-
centage of fat relative to the sum of lean and fat masses.
(D) Ad libitum leptin serum levels at the end of treatment. Dots correspond to individual values and red lines to the average.
(E) Ad libitum triglyceride serum levels at the end of treatment of HFD-fed mice. Dots correspond to individual values and red lines to the average.
(F) Ad libitum cholesterol serum levels at the end of treatment of HFD-fed mice. Dots correspond to individual values and red lines to the average.
Values correspond to the average ± SEM (B) or ± s.d. (C), and statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01,
***p < 0.001. See also Figure S4.aminotransferase (indicative of hepatic damage) and a ten-
dency toward decreased interleukin-6 (IL-6) expression (indica-
tive of hepatic inflammation) (Figures 5B and 5C). Regarding
the adipose tissues of HFD-fed mice, the iBAT and the epidid-
ymal WAT (eWAT) of CNIO-PI3Ki-treated mice showed a564 Cell Metabolism 21, 558–570, April 7, 2015 ª2015 Elsevier Inc.clear reduction in lipid droplets compared with vehicle-treated
mice (Figure 5A). No differences were discernable in SD-fed
mice treated or not with CNIO-PI3Ki. Regarding the WAT,
lipid overload due to HFDs also results in an inflammatory
reaction that includes macrophage infiltration within the WAT
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Figure 5. Reduction of Liver Steatosis and
Macrophage Infiltration in eWAT by Long-
Term CNIO-PI3Ki Treatment
(A) Representative microscopic pictures of liver
sections stained with H&E or oil red O (upper
panels), interscapular BAT (iBAT) sections stained
with H&E or anti-UCP1 (middle panels), and
epididymalWAT (eWAT) sections stainedwith H&E
or anti-F4/80 (lower panels). Bars in the low-
magnification pictures correspond to 200 mm; bars
in the high-magnification insets correspond to
50 mm.
(B) Ad libitum alanine aminotransferase (ALT)
serum levels at the end of long-term treatment.
Dots correspond to individual values and red lines
to the average.
(C) IL-6 expression in liver. Values are relative to
the levels in SD-fed and vehicle-treated mice.
Values correspond to the average ± s.d.
(D) Emr1 and CD68 mRNA levels in eWAT. Values
are relative to the levels in SD-fed and vehicle-
treated mice. Bars correspond to the average ±
s.d.
Statistical significance was determined by the
two-tailed Student’s t test: *p < 0.05. Mice in this
figure are the same as in Figure 4, and all the an-
alyses were performed at the end of the long-term
treatment.(Strissel et al., 2007). Interestingly, the eWAT of CNIO-PI3Ki-
treated HFD-fed mice presented less macrophage infiltration
compared to vehicle-treated and HFD-fed control mice, as
observed using the macrophage marker F4/80 (Figure 5A). A
similar tendency was observed when measuring macrophage
mRNA markers in the eWAT (Figure 5D). Of note, we did not
observe browning in the WAT (Figure 5A). This is in contrast
to the short-term assay where the drug was administered at
higher doses, and we surmise that this is due to the low dose
of drug used in the long-term assay (40-fold lower serum con-
centration compared to the peak of drug achieved by gavage).
Finally, no changes in markers of slow- and fast-twitch fibers
were observed in the gastrocnemius after 2.5 months of treat-
ment with CNIO-PI3Ki (Figure S4C).
We also examined glucose homeostasis in the above groups
of mice after 2.5 months of treatment. However, at this time,
glycemia, insulinemia, glucose tolerance, and the insulin resis-
tance index HOMA-IR were not affected in CNIO-PI3Ki-treatedCell Metabolism 21, 558–HFD-fed mice compared to their controls
(Figures S4D and S4E). Given the fact
that we are using mice with a profound
diabetic profile due to sustained HFD
feeding (8 months), we reasoned that
2.5 months of treatment might not
suffice to improve glucose homeostasis.
To address this, a new assay was per-
formed in which obese mice (that had
been on HFD for 8 months) were exposed
for 5 months to the same dose of CNIO-
PI3Ki (0.1 mg/ml in ad libitum drinkingwater). As before, obese mice treated with CNIO-PI3Ki lost
weight during 50 days and then body weight stabilized at a set
point that was 20% lower than vehicle-treated obese mice (Fig-
ure 6A). This reduction in body weight was maintained during
the following 100 days, as long as the treatment wasmaintained,
thereby implying that chronic treatment does not result in drug
resistance. Of note, withdrawal of treatment resulted in steady
body weight gain, thus indicating that long-term treatment
with CNIO-PI3Ki does not produce irreversible metabolic
alterations. Regarding glucose resistance, HFD-fed mice that
had been treated for 5 months with CNIO-PI3Ki (and then
released from the drug for 1 month) had completely normalized
their fasting glucose levels, being indistinguishable from those
of SD-fed mice (Figure 6B).
Together, the above observations demonstrate that long-term
treatment of HFD-fed mice with a low dose of CNIO-PI3Ki
decreases liver steatosis and adipose tissue inflammation and
improves glucose homeostasis.570, April 7, 2015 ª2015 Elsevier Inc. 565
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Figure 6. Properties of CNIO-PI3Ki on Obesity and Energy Expenditure
(A) Body weight change relative to day 0. Mice of 2 months of age were fed with HFD during 8 months. At this time (day 0), mice were divided into two groups and
treated with vehicle or CNIO-PI3Ki (0.1 mg/ml) in the drinking water during 5 months. At day 155, treatment with vehicle or CNIO-PI3Ki was removed from the
water for the rest of the assay. Mice were fed with HFD during the entire assay. Values correspond to the average ± s.d. C57BL6 males n = 9–10 per group.
Significant weight difference between groups lasted from day 7 to day 180.
(B) Fasting glucose level of HFD-fed mice at the end of the procedure (5 months with treatment and 48 days treatment-free) compared to SD-fed control mice.
(C) Left, performed in the CNIO, body weight change relative to day 0. Mice of 2 months of age were put simultaneously on a HFD with CNIO-PI3Ki (0.1 mg/ml) or
vehicle in the drinkingwater for 20 weeks. Values correspond to the average ± s.d. C57BL6males n = 8–10 per group. Significant weight difference starts at day 3.
(legend continued on next page)
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Increased Energy Expenditure by Long-Term Low-Dose
CNIO-PI3Ki
Next, we asked whether the effects of CNIO-PI3Ki on body
weight were noticeable upon de novo HFD feeding of lean
mice. We took advantage of this new assay to further challenge
the robustness of our observations. Specifically, SD-fed lean
mice were changed to HFD together with the administration of
CNIO-PI3Ki via drinking water (at the CNIO, Madrid) or via
food pellets (at the NIA, Baltimore). In the latter case, the pres-
ence of the drug did not affect food intake (Figure S5A). In both
assays, mice had ad libitum access to water and food, and the
total accumulated daily dose of CNIO-PI3Ki was of approxi-
mately 10 mg/kg (in the case of water the drug was at a concen-
tration of 0.1 mg/ml, and in the case of food it was 0.17 g of drug
per kg of food). Interestingly, the rate of weight gain produced
by the HFD regimen was clearly slowed down in CNIO-PI3Ki-
treated mice compared to vehicle-treated mice, both via drink-
ing water (CNIO) and via food pellets (NIA) (Figure 6C). Also,
CNIO-PI3Ki-treated mice (food, NIA) had lower fasting glucose
levels, thereby implying that the drug protects from the develop-
ment of glucose intolerance (Figure 6D). These observations
indicate that the beneficial effects of PI3K inhibition are
apparent as soon as high-fat feeding starts in healthy lean
mice, and therefore do not require pre-existent metabolic dam-
age by high-fat feeding.
We have previously shown that CNIO-PI3Ki (15 mg/kg via oral
gavage) elevates energy expenditure (Ortega-Molina et al.,
2012). This increase in energy expenditure can be explained, at
least in part, by the activation of thermogenesis in brown adipo-
cytes, both in vivo and in vitro (Ortega-Molina et al., 2012). We
wondered if low-dose CNIO-PI3Ki (food, NIA) had a measurable
impact on energy expenditure. Interestingly, HFD-fed mice
treated with CNIO-PI3Ki via food pellets showed higher constitu-
tive levels of energy expenditure (Figure 6E), oxygen consump-
tion, and CO2 production (Figure S5B). To evaluate iBAT
thermogenesis, wemeasured whole-body and shoulder temper-
ature with a thermographic camera. Mice were anesthetized to
eliminate physical activity, and readings were taken immediately
after anesthesia. As expected, body temperature progressively
dropped, but, interestingly, shoulder temperature was consis-
tently higher in CNIO-PI3Ki-treated mice compared to controls
(Figure 6F). Of note, we also observed higher locomotor activity
in CNIO-PI3Ki-treated mice (Figure S5C), although it remains
debatable to what extent an increase in locomotor activity trans-
lates into an increase in total energy expenditure (Virtue et al.,Right, performed in the NIA, body weight change relative to day 0. Mice of 28 wee
PI3Ki (0.17 g of drug per kg of food) for 12 weeks. Values correspond to the averag
weight were significant after first weight measurement.
(D) Fasting glucose levels of mice after 12 weeks with or without CNIO-PI3Ki trea
assay in (C) (right panel, performed in the NIA). Dots correspond to individual va
(E) Energy expenditure (EE) recorded during 80 hr (left) and mean energy expend
treated mice. Animals (control n = 7; CNIO-PI3Ki n = 8) are from the assay in (C)
(F) Whole-body and shoulder area temperature of mice on HFDwith or without CN
of control lean mice on SD (n = 6–9 per group). Temperature was recorded ever
(G) Body weight change relative to day 0. Hyperphagic ob/ob male mice (12 we
drinking water during 16 weeks. C57BL6 males ob/ob n = 10 per group. Signific
(H) Absolute (left) and relative (right) food intake of ob/ob mice treated with vehicle
4 days, and a total of two periods distributed in the middle of the treatment.
Values correspond to the average ± s.d. Statistical significance was determined
C2012). We conclude that low-dose CNIO-PI3Ki augments energy
expenditure in mice.
Low-Dose CNIO-PI3Ki Treatment Reduces Obesity
in Hyperphagic Mice
Mice deficient in leptin (ob/ob mice) constitute a relevant model
of obesity, which in this case is not due to a high intake of fat, but
to a high intake of standard food due to hyperphagy. Administra-
tion of low dose of CNIO-PI3Ki (via ad libitum drinking water with
the drug at 0.1mg/ml) to ob/obmice for 3months had a dramatic
impact on body weight (Figure 6G). The magnitude of this effect
was even more striking when considering that CNIO-PI3Ki-
treated ob/ob mice were even more hyperphagic than vehicle-
treated ob/ob mice (Figure 6H). In support of our previous
findings with diet-induced obese mice, CNIO-PI3Ki-treated
ob/ob mice had lower levels of serum transaminase ALT (Fig-
ure S5D), decreased hepatic steatosis, and decreased adipo-
cyte size in perirenal and pericardial fat, as well as in iBAT
(Figure S5E). No improvement on glucose homeostasis was
observed in the drug-treated ob/ob mice after 3 months of treat-
ment (Figure S5F). The latter is in line with our previous observa-
tions in diet-induced obese mice, where CNIO-PI3Ki treatment
improved glucose homeostasis after 5 months of treatment,
but not after 2.5 months (see above Figures 6B and S4E). These
results indicate that CNIO-PI3Ki is effective in obese mice fed
with a standard diet.
Low-Dose CNIO-PI3Ki Treatment Reduces Adiposity
in Rhesus Monkeys
Based on the above data in mice, we decided to test the effect of
CNIO-PI3Ki on rhesus monkeys (Macaca mulatta) at the NIH
Animal Center in Poolesville, Maryland. During a preliminary
dosing study (see Supplemental Experimental Procedures),
intravenous administration of 2.1 mg/kg of CNIO-PI3Ki resulted
in a serum concentration of 400 ± 224 ng/ml at 2 hr post-admin-
istration (Figure S6A). This dose was well tolerated based on sta-
ble glucose levels (Figure S6B) and heart rate (Figure S6C), and
the monkeys did not experience any ill effects following the pro-
cedure. Based on this, a study was performed on 19 naturally
obese monkeys (see Supplemental Experimental Procedures)
that were randomly divided into a control group (n = 9) and a
CNIO-PI3Ki-treated group (n = 10). Drug treatment consisted of
daily oral administrationof 2.1mg/kgofCNIO-PI3Ki for 12weeks.
CNIO-PI3Ki concentration in the serum 2 hr post oral administra-
tion was 35 ± 20 ng/ml (Figure S6D), which was 2-fold lowerks of age and fed with SD were put on a HFD or HFD supplemented with CNIO-
e ± s.d. C57BL6males (control n = 18; CNIO-PI3Ki n = 24). Differences in body
tment in their HFD food. Animals (control n = 8; CNIO-PI3Ki n = 8) are from the
lues and red bars to the mean.
iture (right) measured during light and dark period of control and CNIO-PI3Ki-
(right panel, performed in the NIA).
IO-PI3Ki treatment (same animals as in C, right panel, performed in the NIA) and
y second during 10 min.
eks old) fed with SD and treated with vehicle or CNIO-PI3Ki (0.1 mg/ml) in the
ant weight difference between groups starts at day 3.
or CNIO-PI3Ki relative to their body weight. Intake was measured in periods of
by the two-tailed Student’s t test: *p < 0.05, **p < 0.01. See also Figure S5.
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Figure 7. Effects of CNIO-PI3Ki on Obese Rhesus Monkeys
(A) Fold change of adiposity after 12 weeks of treatment with vehicle (n = 9) or
CNIO-PI3Ki (n = 10). Values correspond to the ratio between adiposity at week
12 and adiposity at baseline, for each monkey. Adiposity was measured in the
trunk (adiposity = fat/(fat + lean)%).
(B) Fold change of fasting glucose (same representation as in A) for each
monkey at week 12, relative to baseline.
Statistical significance was determined by the two-tailed Student’s t test. See
also Figure S6.than that observed in mice treated via drinking water with a drug
concentration of 0.1 mg/ml. The obese monkeys were weight
stable at the onset of the treatment, and intake of standard mon-
key chow did not change during the trial (Figure S6E). However,
during the trial, all monkeys received a daily palatable treat that
facilitated the dosing of the drug (control monkeys received the
same treat), which represented a 16% increase in the total calorie
intake (Figure S6E). These additional calories resulted in a small,
but significant, increase in the trunk adiposity of the control group
at the end of the 12-week trial (Figure 7A). Interestingly, in
contrast to the control monkeys, adiposity decreased in the
CNIO-PI3Ki-treated monkeys (Figure 7A). The difference in
adiposity between vehicle-treated andCNIO-PI3Ki-treatedmon-
keys was of 7.6%. No changes were detected in total body
weight in any of the groups (Figure S6F). Additionally, drug-
treated monkeys did not show any sign of discomfort, altered
behavior, or toxicity during the 12-week trial.
Metabolic parameters and blood chemistry variables were
measured before, during, and after the trial (see Supplemental
Experimental Procedures). Importantly, a tendency to decrease
fasting glucose levels was observed (Figure 7B), although no
changes were apparent in the glucose tolerance test (Fig-
ure S6G), fasting insulin levels (Figure S6H), or in the insulin resis-
tance index (HOMA-IR) (Figure S6I). Furthermore, CNIO-PI3Ki
did not affect any of the other metabolic and blood chemistry pa-
rameters tested (see Supplemental Experimental Procedures),
thereby indicating its safety and lack of toxicity at the specified
dose.
We conclude from this trial that CNIO-PI3Ki, at low doses, re-
duces adiposity and may also decrease serum glucose levels in
obese rhesus monkeys, without detectable toxic effects after
12 weeks of daily dosing.
DISCUSSION
Based on previous work by others and us (Becattini et al., 2011;
Chattopadhyay et al., 2011; Foukas et al., 2013; Garcia-Cao
et al., 2012; Kobayashi et al., 2011; Ortega-Molina et al., 2012),
we hypothesized that pharmacological treatment with PI3K568 Cell Metabolism 21, 558–570, April 7, 2015 ª2015 Elsevier Inc.inhibitors could be effective against obesity and metabolic
syndrome. Given the important role of PI3K in insulin signal
transduction, we first measured the acute effects of CNIO-
PI3Ki on fasting glycemia. As expected, oral CNIO-PI3Ki
(15 mg/kg) had a clearly detectable glycemic effect on fasting
mice, thus providing a bona fide biomarker for the activity of
the PI3K inhibitor on insulin signaling. The magnitude of the gly-
cemic peak induced by CNIO-PI3Ki was comparable to a normal
post-prandial glycemia, and it was rapidly reversed after 6 hr,
which reflects the operation of homeostatic control mecha-
nisms. The liver is responsible for the production of glucose dur-
ing fasting, and, indeed, we observed reduced AKT and FOXO1
phosphorylation and elevated expression of the gluconeogenic
gene G6pc. The BAT is another relevant target of PI3K inhibition
(Ortega-Molina et al., 2012) and, consistent with this, we also
observed reduced AKT and FOXO1 phosphorylation together
with an increase in the levels of UCP1 in the iBAT. Increased
expression of Ucp1 was also observed in white adipose depots
suggesting an increased thermogenic activity by the brown adi-
pocytes interspersed within WAT, which are known as brite or
beige adipocytes (Wu et al., 2013). Therefore, PI3K inhibition
produces a transient increase in glycemia within physiological
range, together with an increase in thermogenesis.
We have compared in parallel the anti-obesity activity of two
PI3K inhibitors, CNIO-PI3Ki and GDC-0941, both being highly
specific inhibitors of class IA PI3Ks p110a and p110d, with
similar inhibitory efficacies in vitro, and none of them crossing
the brain-blood barrier (our current data; Ortega-Molina et al.,
2012; Workman et al., 2010). Importantly, both PI3K inhibitors
reduced the weight of obese mice in a dose-dependent manner
and in a short period of 10 days, without affecting their normal
intake of high-fat food. The reduction in body weight was entirely
due to a loss of adiposity, which, upon necropsy, was particularly
prominent in the pericardial fat. Moreover, in the case of the high-
est dose of CNIO-PI3Ki, there was evident browning of the
epididymal, pericardial, and perirenal fat depots. Liver steatosis
also decreased in parallel with the normalization of adiposity.
To simulate a hypothetical clinical application, we tested the
effects of long-term treatment with a low dose of CNIO-PI3Ki
administered through the drinking water, which resulted in
average serum drug levels of 63 ng/ml. This drug concentration
is 40-fold lower than the peak of drug achieved 1–6 hr after oral
gavage of 15 mg/kg. A number of relevant observations were
made. Obese mice treated with CNIO-PI3Ki through the drinking
water lost weight progressively during a period of 50 days, while
maintaining their normal high-fat food intake. Notably, all the
bodyweight loss was due to a reduction in adiposity, while main-
taining a stable lean mass. A slow and progressive weight loss is
a desirable feature because, if translated to humans, it would
allow better medical supervision. Importantly, after 50 days,
treated mice stabilized their body weight at a set point that
was 20% below non-treated obese mice, and this was main-
tained for as long as the treatment was continued. Mice under
chronic treatment with low doses of CNIO-PI3Ki presented
increased energy expenditure, and this can explain the resetting
of energy balance at a lower bodyweight. The stability of the new
energetic balance also suggests that chronic treatment does not
elicit compensatory changes to defend body weight, and it does
not result in drug resistance. Importantly, long-term treatment
with CNIO-PI3Ki produced a range of beneficial effects beyond
body weight loss. In particular, the liver of treated mice pre-
sented decreased steatosis, reduced IL-6 expression, and lower
liver damage (measured by serum transaminases); also, theWAT
had lower levels of inflammation, and serum glucose levels were
normalized after 5 months of treatment. We could not observe
evidence of browning in the WAT when mice were treated with
low doses of drug. Interestingly, the effects of CNIO-PI3Ki on
body weight were reversible upon withdrawal of the treatment,
and mice readjusted their body weight to the same level as con-
trol high-fat-fed mice. This reversibility indicates that long-term
exposure to CNIO-PI3Ki does not produce irreversible alter-
ations in metabolism. In line with this, we did not observe any
evidence of toxic effects in mice even after 5 months of contin-
uous treatment with CNIO-PI3Ki.
In addition to being active in obese high-fat-fed mice, CNIO-
PI3Kiwasalsoactive inhyperphagicob/obmice fedwithstandard
diet. This suggests that the drug is effective against obesity pro-
duced by nutritional overload, independently of the fat content
of the diet. Importantly, CNIO-PI3Ki did not affect the bodyweight
of healthy lean mice under standard diet, which is an attractive
safety feature for a hypothetical human anti-obesity treatment.
Also, CNIO-PI3Ki significantly delayed body weight gain and
glucose intolerance when healthy lean mice were put de novo
on a high-fat diet. This indicates that to be effective the treatment
doesnot requireapre-existent contextof chronichigh-fat feeding.
All together, these three sets of observations (efficacy on ob/ob
mice, lack of effect on mice with standard diet, and efficacy
upon de novo high-fat feeding) point to nutritional overload as
the key requisite for the anti-obesity activity of PI3K inhibition.
Finally, we have extended the efficacy of CNIO-PI3Ki treat-
ment to rhesus monkeys. Obese monkeys were treated for
3monthswith a single daily oral dose of CNIO-PI3Ki that resulted
in serum levels of 35 ng/ml at 2 hr post-dosing. This concentra-
tion of drug can be considered low and comparable to the con-
centration used in the long-term assays in mice (63 ng/ml).
Importantly, treatment with CNIO-PI3Ki produced a modest,
but significant, decrease in adiposity (7.6% reduction) and a
trend toward lowered serum glucose. No toxic effects were
observed in any monkey during the 12 weeks of treatment.
Based on the evidence presented here in mice and monkeys,
we propose that moderate pharmacological inhibition of PI3K
can be an effective and safe therapeutic strategy against human
obesity and metabolic syndrome.
EXPERIMENTAL PROCEDURES
PI3K Inhibitors
The low-molecular-weight compound CNIO-PI3Ki is described in patent
WO2010/119264 (files available at theWorld Intellectual PropertyOrganization,
http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2010119264). The
kinase activity of PI3K isoformswasmeasured by using the commercial PI3-ki-
nase (h) HTRF assay available fromMillipore, following themanufacturer’s rec-
ommendations. PI3Ka (p110a/p85a) and PI3Kd (p110d/p85a) were used at
100 pM; and PI3Kb (p110b/p85a) and PI3Kg isoforms (p110g) at 500 pM and
4 nM, respectively. ATP concentration was 50 times KM
ATP: 200 mM for
PI3Ka and PI3Kd, 250 mM for PI3Kb, and 100 mM for PI3Kg. PIP2 was held
at 10 mM. Values were normalized against the control activity included for
each enzyme (i.e., 100% PI3K activity, without compound). These values
were plotted against the inhibitor concentration and were fitted to a sigmoidal
dose-response (variable slope) curve by usingGraphPad software. In addition,Ca total of 284 kinases (Table S1) weremeasured by ProQinase. Details of assay
conditions can be found at http://www.proqinase.com.
Mouse Experimentation
All animal procedures done at the CNIO were performed according to proto-
cols approved by the CNIO-ISCIII Ethics Committee for Research and Animal
Welfare (CEIyBA). All animal protocols done at the NIA were approved by the
Animal Care and Use Committee of the National Institute on Aging (Balti-
more). Mice were housed under specific pathogen-free (SPF) conditions, at
22C, and with 12-hr dark/light cycles (light cycle from 8:00am to 8:00pm).
Mice were fed either with a standard chow diet (Harlan Teklad 2018; 18% cal-
ories from fat) or, when indicated, with a HFD (Research Diets D12451; 45%
of total calories from fat). For gavage administration, CNIO-PI3Ki and GDC-
0941 were dissolved in PEG-300 and 10% N-methyl-2-pyrrolidone. For
administration in the drinking water, CNIO-PI3Ki was dissolved in 1.8% cyclo-
dextrin (Sigma). For administration in the food, HFD (AIN-93G diet modified to
provide 60% of calories from fat) supplemented with CNIO-PI3Ki at a dose of
0.17 g of drug per kg of food was manufactured by Dyets (Bethlehem).
Monkey Experimentation
All procedures were approved by the Animal Care and Use Committee of the
NIA Intramural Research Program. Rhesus monkeys (Macaca mulatta) were
housed at the NIH Animal Center in Poolesville, Maryland. Monkeys were fed
commercially prepared monkey chow that was distributed twice daily along
with daily food enrichment, and water was available ad libitum. During the
study, animals were supplemented with 5 or 6 PRIMA-treat wafers (Bio-Serv;
assorted fruit flavors, F0345; each wafer weighs 5 g with 3.28 kcal/g). The
PRIMA-treat wafers were used as vehicle for CNIO-PI3Ki. Individually weighed
doses of CNIO-PI3Ki were reconstituted in water and then distributed, via
syringe, onto the PRIMA-treats. Once absorbed, they were fed to the animals.
Drug administration continued daily (weekends included) for 12 weeks.
Immunohistochemistry, Protein, RNA, Cellular, and Metabolic
Analyses
Immunohistochemistry, protein, RNA, cellular, and metabolic analyses were
performed following standard procedures as detailed in Supplemental
Information.
Statistical Analysis
Unless otherwise specified, data are presented as average ± s.d. Statistical
significance was assessed in most cases using the two-tailed unpaired Stu-
dent’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2015.02.017.
AUTHOR CONTRIBUTIONS
A.O.-M. initiated the study, performed part of the mouse studies at the CNIO,
and contributed to experimental design, data analysis, discussion, and writing
of the paper; E.L.-G. completed themouse studies at the CNIO, participated in
the monkey studies at the NIA, and contributed to experimental design, data
analysis, discussion, and writing of the paper; M.M.-M. and G.I. helped with
mouse experimentation at the CNIO; S.J.M. and V.M.G. performed mouse
studies at the NIA; J.A.M., K.L.V., and M.D.S. contributed to the experimental
design, experimentation, data analysis, and interpretation of the monkey
studies; D.C. quantified the drugs by mass spectrometry and performed the
pharmacokinetic assays; I.G.-G. and M.L. performed the analysis of hypotha-
lamic neuropeptides in the arcuate nucleus; S.M. and J.P. designed, synthe-
sized, and characterized the small organic compound CNIO-PI3Ki; R.d.C. de-
signed, supervised, and secured funding for the studies at the NIA and
contributed to writing of the paper; M.S. designed and supervised the study,
secured funding for the studies at the CNIO, and wrote the manuscript. All au-
thors discussed the results and commented on the manuscript.ell Metabolism 21, 558–570, April 7, 2015 ª2015 Elsevier Inc. 569
ACKNOWLEDGMENTS
Weare grateful to FranciscaMulero for the DXA analyses andMarta Can˜amero
for histology. Work in the laboratory of M.S. was funded by the CNIO and by
grants from the Spanish Ministry of Economy (SAF), the European Research
Council (ERC Advanced Grant), the Regional Government of Madrid, the Botin
Foundation and Banco Santander (Santander Universities Global Division), the
Ramon Areces Foundation, and the AXA Foundation. Work in the laboratory of
R.d.C. was funded, in part, by the Intramural Research Program of the NIA
(NIH). Work in the laboratory of M.L. was funded by the European Research
Council (ERC Starting Grant) and Xunta de Galicia. The funders had no role
in study design, data collection and analysis, decision to publish, or prepara-
tion of the manuscript. A.O.-M. was recipient of a predoctoral contract from
the Regional Government of Madrid. E.L.-G. and I.G.-G. were recipients of a
predoctoral contract from the Spanish Ministry of Education. Some of the
authors (A.O.-M., S.M., J.P., and M.S.) are inventors in patents covering
CNIO-PI3Ki and the use of PI3K inhibitors for obesity.
Received: December 7, 2014
Revised: January 30, 2015
Accepted: February 19, 2015
Published: March 26, 2015
REFERENCES
Barzilai, N., Huffman, D.M., Muzumdar, R.H., and Bartke, A. (2012). The critical
role of metabolic pathways in aging. Diabetes 61, 1315–1322.
Becattini, B., Marone, R., Zani, F., Arsenijevic, D., Seydoux, J., Montani, J.P.,
Dulloo, A.G., Thorens, B., Preitner, F., Wymann, M.P., and Solinas, G. (2011).
PI3Kg within a nonhematopoietic cell type negatively regulates diet-induced
thermogenesis and promotes obesity and insulin resistance. Proc. Natl.
Acad. Sci. USA 108, E854–E863.
Cava, E., and Fontana, L. (2013). Will calorie restriction work in humans? Aging
(Albany, N.Y. Online) 5, 507–514.
Chattopadhyay, M., Selinger, E.S., Ballou, L.M., and Lin, R.Z. (2011). Ablation
of PI3K p110-a prevents high-fat diet-induced liver steatosis. Diabetes 60,
1483–1492.
Colman, R.J., Anderson, R.M., Johnson, S.C., Kastman, E.K., Kosmatka, K.J.,
Beasley, T.M., Allison, D.B., Cruzen, C., Simmons, H.A., Kemnitz, J.W., and
Weindruch, R. (2009). Caloric restriction delays disease onset and mortality
in rhesus monkeys. Science 325, 201–204.
Cone, R.D., Cowley, M.A., Butler, A.A., Fan, W., Marks, D.L., and Low, M.J.
(2001). The arcuate nucleus as a conduit for diverse signals relevant to energy
homeostasis. Int. J. Obes. Relat. Metab. Disord. 25, S63–S67.
Fontana, L., Partridge, L., and Longo, V.D. (2010). Extending healthy life
span—from yeast to humans. Science 328, 321–326.
Foukas, L.C., Bilanges, B., Bettedi, L., Pearce, W., Ali, K., Sancho, S., Withers,
D.J., and Vanhaesebroeck, B. (2013). Long-term p110a PI3K inactivation ex-
erts a beneficial effect on metabolism. EMBO Mol. Med. 5, 563–571.
Garcia-Cao, I., Song, M.S., Hobbs, R.M., Laurent, G., Giorgi, C., de Boer, V.C.,
Anastasiou, D., Ito, K., Sasaki, A.T., Rameh, L., et al. (2012). Systemic elevation
of PTEN induces a tumor-suppressive metabolic state. Cell 149, 49–62.
Goren, H.J., Kulkarni, R.N., and Kahn, C.R. (2004). Glucose homeostasis and
tissue transcript content of insulin signaling intermediates in four inbred strains
of mice: C57BL/6, C57BLKS/6, DBA/2, and 129X1. Endocrinology 145, 3307–
3323.
Gurevich-Panigrahi, T., Panigrahi, S., Wiechec, E., and Los, M. (2009).
Obesity: pathophysiology and clinical management. Curr. Med. Chem. 16,
506–521.
Kaur, J. (2014). A comprehensive review onmetabolic syndrome. Cardiol. Res.
Pract. 2014, 943162.
Kenyon, C.J. (2010). The genetics of ageing. Nature 464, 504–512.570 Cell Metabolism 21, 558–570, April 7, 2015 ª2015 Elsevier Inc.Kobayashi, N., Ueki, K., Okazaki, Y., Iwane, A., Kubota, N., Ohsugi, M.,
Awazawa, M., Kobayashi, M., Sasako, T., Kaneko, K., et al. (2011).
Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced
inflammation and insulin resistance. Proc. Natl. Acad. Sci. USA 108, 5753–
5758.
Mattison, J.A., Roth, G.S., Beasley, T.M., Tilmont, E.M., Handy, A.M., Herbert,
R.L., Longo, D.L., Allison, D.B., Young, J.E., Bryant, M., et al. (2012). Impact of
caloric restriction on health and survival in rhesusmonkeys from the NIA study.
Nature 489, 318–321.
Mercken, E.M., Crosby, S.D., Lamming, D.W., JeBailey, L., Krzysik-Walker, S.,
Villareal, D.T., Capri, M., Franceschi, C., Zhang, Y., Becker, K., et al. (2013).
Calorie restriction in humans inhibits the PI3K/AKT pathway and induces a
younger transcription profile. Aging Cell 12, 645–651.
Mun˜oz-Espı´n, D., Can˜amero, M., Maraver, A., Go´mez-Lo´pez, G., Contreras,
J., Murillo-Cuesta, S., Rodrı´guez-Baeza, A., Varela-Nieto, I., Ruberte, J.,
Collado, M., and Serrano, M. (2013). Programmed cell senescence during
mammalian embryonic development. Cell 155, 1104–1118.
Ortega-Molina, A., Efeyan, A., Lopez-Guadamillas, E., Mun˜oz-Martin, M.,
Go´mez-Lo´pez, G., Can˜amero, M., Mulero, F., Pastor, J., Martinez, S.,
Romanos, E., et al. (2012). Pten positively regulates brown adipose function,
energy expenditure, and longevity. Cell Metab. 15, 382–394.
Pal, A., Barber, T.M., Van de Bunt, M., Rudge, S.A., Zhang, Q., Lachlan, K.L.,
Cooper, N.S., Linden, H., Levy, J.C., Wakelam, M.J., et al. (2012). PTENmuta-
tions as a cause of constitutive insulin sensitivity and obesity. N. Engl. J. Med.
367, 1002–1011.
Perino, A., Beretta, M., Kilic, A., Ghigo, A., Carnevale, D., Repetto, I.E.,
Braccini, L., Longo, D., Liebig-Gonglach, M., Zaglia, T., et al. (2014).
Combined inhibition of PI3Kb and PI3Kg reduces fat mass by enhancing
a-MSH-dependent sympathetic drive. Sci. Signal. 7, ra110.
Pi-Sunyer, X. (2009). The medical risks of obesity. Postgrad. Med. 121, 21–33.
Puigserver, P., Herron, D., Gianotti, M., Palou, A., Cannon, B., and
Nedergaard, J. (1992). Induction and degradation of the uncoupling protein
thermogenin in brown adipocytes in vitro and in vivo. Evidence for a rapidly
degradable pool. Biochem. J. 284, 393–398.
Salphati, L., Heffron, T.P., Alicke, B., Nishimura, M., Barck, K., Carano, R.A.,
Cheong, J., Edgar, K.A., Greve, J., Kharbanda, S., et al. (2012). Targeting
the PI3K pathway in the brain—efficacy of a PI3K inhibitor optimized to cross
the blood-brain barrier. Clin. Cancer Res. 18, 6239–6248.
Sohn, J.W., Elmquist, J.K., and Williams, K.W. (2013). Neuronal circuits that
regulate feeding behavior and metabolism. Trends Neurosci. 36, 504–512.
Strissel, K.J., Stancheva, Z., Miyoshi, H., Perfield, J.W., 2nd, DeFuria, J., Jick,
Z., Greenberg, A.S., and Obin, M.S. (2007). Adipocyte death, adipose tissue
remodeling, and obesity complications. Diabetes 56, 2910–2918.
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., and Bilanges, B.
(2010). The emerging mechanisms of isoform-specific PI3K signalling. Nat.
Rev. Mol. Cell Biol. 11, 329–341.
Virtue, S., and Vidal-Puig, A. (2010). Adipose tissue expandability, lipotoxicity
and the metabolic syndrome—an allostatic perspective. Biochim. Biophys.
Acta 1801, 338–349.
Virtue, S., Even, P., and Vidal-Puig, A. (2012). Below thermoneutrality, changes
in activity do not drive changes in total daily energy expenditure between
groups of mice. Cell Metab. 16, 665–671.
Workman, P., Clarke, P.A., Raynaud, F.I., and van Montfort, R.L. (2010).
Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer
Res. 70, 2146–2157.
Wu, J., Cohen, P., and Spiegelman, B.M. (2013). Adaptive thermogenesis in
adipocytes: is beige the new brown? Genes Dev. 27, 234–250.
Yeo, G.S., and Heisler, L.K. (2012). Unraveling the brain regulation of appetite:
lessons from genetics. Nat. Neurosci. 15, 1343–1349.
